MPM Capital is a leading biotechnology investment firm investing in early-stage therapeutics companies. David S. Bredt, MD, PhD, has joined its team of Executive Partners.

Before joining MPM, David was Site Head for Johnson & Johnson’s R&D Campus in La Jolla, which focuses on Neuroscience, Immunology and Biotechnology and is the original JLABS incubator for emerging healthcare companies. He was Global Head of Neuroscience Discovery at Johnson & Johnson where he had line management responsibility for neuroscience biology, biomarkers, and external innovation activities. His discovery group delivered numerous small and large molecule clinical candidates for Alzheimer’s disease, major depression, schizophrenia and epilepsy.

David joined Eli Lilly and Company as Vice President of Integrative Biology in August 2004 and became Vice President of Neuroscience Discovery and Early Development a few years later. As head of neuroscience research at Eli Lilly, David’s group was responsible for Discovery through Phase 2 programs in Neurology, Psychiatry, Migraine, and Pain indications. His group prosecuted numerous small and large molecules that entered preclinical and clinical development including galcanezumab / Emgality, which is now approved for preventative treatment of migraine.